February 28, 2017 - 10:00 AM
February 28, 2017 - 11:30 AM
Assessment of Needs
The IAS–USA offers this state-of-the-art activity on the evolving challenges of managing HIV disease as part of a nationwide continuing medical education (CME) effort for physicians. This webinar will summarize the most recent and clinically relevant information to be presented at the 2017 Conference on Retroviruses and Opportunistic Infections held in Seattle, Washington, in February. This overview will include updates on antiretroviral therapy and investigational antiretroviral drugs. The most up-to-date data on HIV drug resistance, HIV prevention, and national and global epidemiology will be discussed during this webinar. New data on comorbidities and coinfections such as tuberculosis and hepatitis C virus infection will also be discussed.
At the conclusion of this webinar, participants will be able to:
- Describe the newest data on antiretroviral therapy
- Name trends in HIV drug resistance
- Interpolate the most recent data into clinical practice
Who Should Attend
This webinar is designed for clinicians who have solid, working knowledge of HIV transmission, screening, and management, and who are actively treating patients with HIV infection.
This activity is also relevant for other practitioners, including nurse practitioners and other nursing professionals, physician assistants, and pharmacists.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Monday, February 27, 2017, 4:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at registration“at”iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hours (0.15 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-17-012-L02-P
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.